Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Axsome Therapeutics, Inc. ( AXSM ) H.C. Wainwright 28th Annual Global Investment Conference September 16, 2026 10:00 AM EDT Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie - Chief Financial Officer Presentation Operator Good morning, everyone, and welcome to the H.C. Wainwright 28th Annual Global Investment Conference. I'm [ Katherine Dagan ], and I'll be your moderator for today. It's our pleasure to welcome Mark Jacobson, COO; and Nick Pizzie, CFO of Axsome Therapeutics. Thank you both for being here. Take it away. Mark Jacobson Chief Operating Officer Great. Thanks very much for having us, and good morning, everyone. Nice to be here and see you all. So we're actually going to take you through today and the corporate presentation instead of a fireside chat, we want to take a moment to really share how the business has grown and where it is in this very, I think, unique stage of development that we're pretty excited about. First and foremost, we will be making forward-looking statements today or we may be, and we'd encourage you to read a full summary of the risks and uncertainties associated with our business through our filings at the Securities and Exchange Commission. So with that, we'll get started. So Axsome Therapeutics, we are focused on central nervous system disorders, in particular, highly differentiated mechanisms of actions for areas of unmet need or that have been underserved in CNS. And that's -- we think about it for psychiatry and neurology. The snapshot of the business today is 3 marketed products, Auvelity, Sunosi and SYMBRAVO. Auvelity is approved for major depressive disorder and recently, Alzheimer's disease agitation, which we are launching now, Sunosi for excessive daytime sleepiness in OSA or narcolepsy and then SYMBRAVO for migraine. We'll talk more about each of those. We have 6